glp 1 glucagon receptor pathway AdipoGen Glucagon-like peptide-1: Trends in Endocrinology

GLP-1RA

[9] [5] It is given by mouth, by injection into a muscle, or as a nasal spray

Potential risks and contraindications Given the limited understanding of DSIPs mechanisms and effects in humans, certain risks and contraindications must be taken into consideration: Unknown long-term effects : The long-term safety of DSIP has not been well-established, and the potential risks associated with chronic use remain unclear

Instructions for reconstitution The injection is given into the sub-cutaneous layer which includes adipose tissue (fat)

10.1136/gutjnl-2014-308410 29 DukicM.RadonjicT.JovanovicI.ZdravkovicM.TodorovicZ.KraisnikN.et al (2023)